Hepatoma rates are rising, especially among incarcerated patients. Risk factor mitigation and early detection will produce the best treatment outcomes. Screening modalities of ultrasound and multiphase MRI/CT are key to identifying patients with hepatoma. Therapy options need to be tailored to disease burden, liver reserves, and patient?s performance status as well as DOC regulations. This session will discuss these important considerations, as well as the need for on-site staff to recognize therapy complications to prevent excessive toxicity.

• Review the etiology of cirrhosis
• Describe screening methods for hepatoma
• Discuss current hepatoma treatment options

Level: Basic